Table 2: Differences before and after treatment
between SPIRO and AMLO groups.
Variable |
SPIRO diff. (CI 95%) |
AMLO diff. (CI 95%) |
Effect |
P-value |
FPG (mg/dL) |
0.8 (-2.53:4.13) |
5.5 (1.37:9.57) |
-4.7 (-10.25:0.90) |
0.096 |
HOMA - IR |
0.2 (-0.60:0.92) |
0.8 (-0.17:1.75) |
-0.6 (-1.86:0.61) |
0.306 |
Potassium (mEq/L) |
0.1 (-0.03:0.33) |
0.1 (-0.08:0.35) |
0.0 |
0.907 |
HDL-cholesterol (mg/dL) |
4.6 (1.88:7.32) |
1.8 (-1.44:5.15) |
2.7 (-1.6:7.07) |
0.202 |
Triglycerides (mg/dL) |
-14.1 (-35.90:7.67) |
-22.7 (-48.36:4.33) |
7.9 (-26.52: 42.33) |
0.639 |
hs-CRP (mg/L) |
-1.0 (-1.93:-0.69) |
1.9 (0.81:3.06) |
-2.9 (-4.42:-1.45) |
0.000 |
Plasma aldosterone (ng/dL) |
9.15 (5.7:12.5) |
0.83 (-3.75:5.41) |
8.3 (2.53:14.11) |
0.007 |
Urinary albumin excretion (mg/g creatinine) |
-10.9 (-19.79:-1.99) |
-0.19 (-11.62:11.23) |
-10.7 (-25.63:4.24) |
0.152 |
FMD (%) |
4.9 (2.18:7.70) |
-3.9 (-7.25:-0.54) |
8.8 (4.39:13.28) |
0.000 |
hs-CRP: C Reactive Protein-high sensitivity;
Diff: Difference after-before treatment; Effect: Differences between
differences in each group; FMD: Flow Mediated Dilation; FPG: Fasting Plasma
Glucose; HDL: High Density Lipoprotein; HOMA IR: Homeostasis Model Assessment
of Insulin Resistance.